Last updated: April 27, 2026
Who Supplies Dutasteride and Tamsulosin Hydrochloride for Generic Drug Manufacturing?
Dutasteride and tamsulosin hydrochloride are widely sourced APIs and intermediates, with supply anchored in a short list of global API manufacturers plus a deeper bench of intermediate suppliers. The manufacturing and commercial supply chain typically splits into (1) API manufacturers that supply the final API to generic formulators and (2) intermediate producers that feed captive or contract API routes.
Below is a practical supplier map by drug substance. (This covers established commercial API supply and common intermediate ecosystems used for Abbreviated New Drug Applications and other generic routes.)
Dutasteride: Who Supplies the API and Common Intermediates?
API suppliers (global commercial manufacturers)
Commonly cited commercial suppliers include:
- Aurobindo Pharma (India)
- Dr. Reddy’s Laboratories (India)
- Sun Pharmaceutical Industries (India)
- Zydus Lifesciences (India)
- Alkem Laboratories (India)
- Cipla (India)
- Macleods Pharmaceuticals (India)
- Cadila Healthcare (India)
- Divi’s Laboratories (India)
International/API-focused firms that also participate in generic API supply chains:
- Teva API (multiple manufacturing sites globally; branded via Teva group historically)
- Sandoz (via Novartis group supply; often downstream, sometimes indirect access via contract manufacturing)
Intermediate supplier pattern (how supply actually gets built)
Dutasteride API supply usually depends on upstream intermediates built through multi-step routes centered on steroid-core chemistry and late-stage functional group installation. The intermediate supplier market is larger than the final API market, and many intermediate makers sell to multiple API producers.
In practice, generic manufacturers qualify one or two API sources per strength and hold at least a secondary supply for continuity.
Tamsulosin Hydrochloride: Who Supplies the API and Common Intermediates?
API suppliers (global commercial manufacturers)
Commercial API suppliers commonly include:
- Zydus Lifesciences (India)
- Sun Pharmaceutical Industries (India)
- Dr. Reddy’s Laboratories (India)
- Aurobindo Pharma (India)
- Cipla (India)
- Alkem Laboratories (India)
- Divi’s Laboratories (India)
- Mylan (now Viatris) API network (availability varies by site and contract)
International supply participants:
- Teva API (group-level supply)
- Sandoz (group-level supply)
Intermediate supplier pattern
Tamsulosin hydrochloride routes focus on an aniline-type scaffold and controlled installation of the ether and amine features that drive selectivity. The intermediate ecosystem is dense, so API availability often depends less on “single intermediate scarcity” and more on compliance and batch release continuity.
How Supply Qualification Works for Dutasteride + Tamsulosin Combination Products
Typical qualification requirements for generic formulators
For combination products, the formulation site needs:
- Consistent particle and polymorph behavior of each API
- Robust impurity profiles and residual solvent controls tied to the synthetic route
- Stability data aligned to label storage conditions
- CoA batch-to-batch traceability and established change control history
Procurement practice
Most generic program managers hedge supply by:
- Holding two qualified API suppliers per API
- Using a second source that matches the same grade (often “pharmaceutical grade” with defined impurity limits)
- Aligning impurity specs with the planned analytical method package
Supplier Selection Checklist (API + Compliance)
Use this filter on any supplier shortlist:
- Regulatory track record: EMA/FDA/WHO DMF presence (or equivalent disclosure under local dossiers)
- Site history: established commercial production and audit cadence
- Impurity control: ability to meet ICH Q3A and product-specific limits for specified related substances
- Salt form readiness: tamsulosin hydrochloride supplied as hydrochloride with verified salt stability
- Documentation: CoA, stability protocol, and change control commitments
Key Takeaways
- Dutasteride and tamsulosin hydrochloride are supported by a core group of India-based API manufacturers with broad global reach.
- Supply tends to be resilient due to a deep intermediate ecosystem, but qualification and impurity control determine which sources can be used for combination products.
- Generic programs typically qualify one primary and one backup supplier per API to manage continuity, compliance, and batch release risk.
FAQs
1) Are dutasteride and tamsulosin hydrochloride usually sourced as APIs (not formulated intermediates)?
Yes. Most generic manufacturers source the finished APIs (dutasteride API and tamsulosin hydrochloride API) and formulate tablets or capsules to the approved reference product specifications.
2) Do suppliers change frequently for these APIs?
API supply is relatively stable, but the usable supplier set can change based on regulatory status, audit outcomes, and route-specific impurity profiles.
3) Is tamsulosin hydrochloride commonly available from multiple suppliers?
Yes. Multiple established commercial API producers supply the hydrochloride form, though salt form consistency and impurity performance are gating items for qualification.
4) What matters most for qualification in combination products?
Consistency of impurity patterns, physical characteristics (relevant to dissolution and stability), and documentation supporting controlled manufacturing changes.
5) Can an API supplier provide both drugs?
Some manufacturers operate broad API portfolios and may supply one or both drugs. Program teams still qualify each API independently.
References
- FDA Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations (Dutasteride and Tamsulosin Hydrochloride combination and individual listings). U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/
- EMA product-related information and EPAR documents for dutasteride and tamsulosin hydrochloride products. European Medicines Agency. https://www.ema.europa.eu/
- ICH Guidelines: Q3A (Impurities in New Drug Substances) and Q3B (Impurities in New Drug Products). International Council for Harmonisation. https://www.ich.org/
